Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs

Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.Material and methods...

Full description

Bibliographic Details
Main Authors: S. V. Nedogoda, E. V. Chumachek, V. V. Tsoma, A. S. Salasyuk, V. O. Smirnova, E. A. Popova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2019-02-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/3097
_version_ 1797856818940084224
author S. V. Nedogoda
E. V. Chumachek
V. V. Tsoma
A. S. Salasyuk
V. O. Smirnova
E. A. Popova
author_facet S. V. Nedogoda
E. V. Chumachek
V. V. Tsoma
A. S. Salasyuk
V. O. Smirnova
E. A. Popova
author_sort S. V. Nedogoda
collection DOAJ
description Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.Material and methods. In open observational study with 24 weeks follow-up were included 60 patients with previous therapy (losartan or valsartan or telmisartan).All patients underwent ambulatory BP monitoring, applanation tonometry (determination of the augmentation index and central BP), measurement of the pulse wave velocity, laboratory tests (lipid profile, uric acid, fasting glucose, Homeostasis Model Assessment, homocysteine, leptin, adiponectin, highly sensitive C-reactive protein, tumor necrosis factor alpha, interleukin-6).Results. Azilsartan provided the systolic BP (29,05%, 22,5% and 8,9%) and diastolic BP reduction 18,82%, 20,46% and 8,54% (p<0,05) in patients previously treated with losartan, valsartan or telmisartan, respectively. Central systolic BP (by 25,95%, 8,78%, 11,94%), central pulse BP (by 40%, 18,38% and 19,6%), augmentation index (by 28,87%, 20,69% and 14,29%) and pulse wave velocity (by 21,57%, 24,56% and 24,92%) were decreased (p<0,05). There were positive changes in leptin, C-reactive protein, IL-6, adiponectin levels in all patients with losartan, valsartan or telmisartan initial therapy (p<0,05).Conclusion. Azilsartan medoxomil has advantages in BP control, the arterial elasticity improving, reducing of insulin-resistance and inflammation.
first_indexed 2024-04-09T20:46:35Z
format Article
id doaj.art-7bd1ff905efe4b399de56cdf219c1018
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:46:35Z
publishDate 2019-02-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-7bd1ff905efe4b399de56cdf219c10182023-03-29T21:23:32Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202019-02-0101707910.15829/1560-4071-2019-1-70-792557Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBsS. V. Nedogoda0E. V. Chumachek1V. V. Tsoma2A. S. Salasyuk3V. O. Smirnova4E. A. Popova5Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityAim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.Material and methods. In open observational study with 24 weeks follow-up were included 60 patients with previous therapy (losartan or valsartan or telmisartan).All patients underwent ambulatory BP monitoring, applanation tonometry (determination of the augmentation index and central BP), measurement of the pulse wave velocity, laboratory tests (lipid profile, uric acid, fasting glucose, Homeostasis Model Assessment, homocysteine, leptin, adiponectin, highly sensitive C-reactive protein, tumor necrosis factor alpha, interleukin-6).Results. Azilsartan provided the systolic BP (29,05%, 22,5% and 8,9%) and diastolic BP reduction 18,82%, 20,46% and 8,54% (p<0,05) in patients previously treated with losartan, valsartan or telmisartan, respectively. Central systolic BP (by 25,95%, 8,78%, 11,94%), central pulse BP (by 40%, 18,38% and 19,6%), augmentation index (by 28,87%, 20,69% and 14,29%) and pulse wave velocity (by 21,57%, 24,56% and 24,92%) were decreased (p<0,05). There were positive changes in leptin, C-reactive protein, IL-6, adiponectin levels in all patients with losartan, valsartan or telmisartan initial therapy (p<0,05).Conclusion. Azilsartan medoxomil has advantages in BP control, the arterial elasticity improving, reducing of insulin-resistance and inflammation.https://russjcardiol.elpub.ru/jour/article/view/3097arterial hypertensionpulse wave velocitycentral blood pressureaugmentation indexadipokinesazilsartan
spellingShingle S. V. Nedogoda
E. V. Chumachek
V. V. Tsoma
A. S. Salasyuk
V. O. Smirnova
E. A. Popova
Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
Российский кардиологический журнал
arterial hypertension
pulse wave velocity
central blood pressure
augmentation index
adipokines
azilsartan
title Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
title_full Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
title_fullStr Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
title_full_unstemmed Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
title_short Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
title_sort effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other arbs
topic arterial hypertension
pulse wave velocity
central blood pressure
augmentation index
adipokines
azilsartan
url https://russjcardiol.elpub.ru/jour/article/view/3097
work_keys_str_mv AT svnedogoda effectivenessofininsulinresistancecorrectionandtheadipokineslevelreductioninpatientswitharterialhypertensionincomparisonwithotherarbs
AT evchumachek effectivenessofininsulinresistancecorrectionandtheadipokineslevelreductioninpatientswitharterialhypertensionincomparisonwithotherarbs
AT vvtsoma effectivenessofininsulinresistancecorrectionandtheadipokineslevelreductioninpatientswitharterialhypertensionincomparisonwithotherarbs
AT assalasyuk effectivenessofininsulinresistancecorrectionandtheadipokineslevelreductioninpatientswitharterialhypertensionincomparisonwithotherarbs
AT vosmirnova effectivenessofininsulinresistancecorrectionandtheadipokineslevelreductioninpatientswitharterialhypertensionincomparisonwithotherarbs
AT eapopova effectivenessofininsulinresistancecorrectionandtheadipokineslevelreductioninpatientswitharterialhypertensionincomparisonwithotherarbs